SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending, and the community is actively engaging with the classic "What's UpDog?" joke, driving social volume. Some users are pointing out the project has been live on Solana for over a year and has a locked and burned LP. Others suggest the recent increase in social volume is due to only one or two accounts.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors anticipate upcoming earnings, with community members highlighting the potential impact of QNX technology and key partnerships with companies like AMD and Nvidia. Bullish sentiment is fueled by expectations of strong financial performance and the possibility of future share buybacks. Some investors suggest BlackBerry is undervalued, drawing comparisons to AMD's earlier growth trajectory.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MLTX is trending due to positive Phase 2 trial data for its drug sonelokimab in treating hidradenitis suppurativa, leading to raised price targets and speculation about its potential as a best-in-class treatment. The community is actively discussing the implications of this data, especially compared to competitors, and the possibility of a future buyout. Some investors believe MLTX is thoroughly de-risked.

Blockchain-on-Blockchain (BOB) is a new blockchain built on top of another blockchain called ICP. It's like a special layer on an existing system. BOB creates a secure digital record book that uses ICP's network for safety. BOB uses a system called 'proof-of-on-chain-work': You deploy your own smart contract (canister) at bob.fun. This program solves math problems (hashes). Main computers (mother nodes) give out these problems. Miners solve the problems and tell the mother node. If correct, the mother node adds a new block to the blockchain. The winning miner gets BOB tokens as a reward.

BOB.X is trending as users discuss its potential as the next BTC.X, highlighting its capped supply and upcoming halving event. Community members are also excited about its multi-chain availability and integration within the ICP.X ecosystem.

WeRide, Inc. is a holding company, which engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers, and related sensor suites. The company was founded by Tony Xu Han and Yan Li on March 13, 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide ($WRD) is trending due to discussions around its partnerships and deployments in the Middle East and Southeast Asia, including Singapore and Abu Dhabi. The community is debating whether WeRide is undervalued compared to competitors like Pony.ai, despite its revenue growth and expansion. Recent news of UBS initiating coverage with a buy rating and the upcoming Grab earnings call are also fueling interest.

Invesco DB US Dollar Index Trust - Invesco DB US Dollar Index Bullish Fund

Invesco DB US Dollar Index Bullish Fund

The U.S. Dollar Index ($UUP) is trending as traders weigh the potential impact of a strong dollar against expectations for future Federal Reserve policy. Community members are analyzing technical indicators and potential breakout levels, while also considering the impact of tariffs and trade deals. Discussions revolve around the dollar's relationship with other asset classes like gold and equities.

ProShares Trust - ProShares VIX Short-Term Futures ETF

ProShares VIX Short-Term Futures ETF

VIXY is trending as traders discuss potential market volatility driven by factors like geopolitical tensions (Middle East), tariff concerns, and economic data. Community members are actively analyzing yearly charts and technical patterns, with some anticipating a volatility spike and hedging their portfolios, while others point to the potential for market manipulation.

Meet Pandu — your AI friend who’s always by your side. Talk with him in real time through text or voice, share your thoughts, ask questions, or just enjoy a casual conversation. Whether you’re looking for advice, company, or simply someone to listen, Pandu is here as a true companion you can connect with anytime.  Pandu unites real-time conversation, creative generation, and future-ready AI systems — all powered by next-gen technology.

Pandu Pandas

Pandu Pandas is trending as the community discusses its recent listing on MEXC and potential for significant growth. Comparisons to other tokens like PENGU are circulating, with many highlighting its strong fundamentals and NFT presence. Holders are expressing bullish sentiment, anticipating a potential breakout and encouraging others to research the token.

its a Meme token and beta to Troll The "Lenny face  is a text-based emoticon, ( ͡° ͜ʖ ͡°), used to convey a range of emotions, particularly mischief, sexual innuendo, or a hidden meaning. It's often employed in online discussions to add a playful or suggestive tone to a message, or sometimes even to spam threads, according to Wikipedia. The symbol is visually interpreted as a face with two eyes (small circles), a nose (squiggly line), and a mouth (curved line).

Lenny

$LENNY.X is trending as the 'OG face of the internet' aims to build a strong community and 'Lenny Cult'. Social media mentions highlight conviction and relentless grinding towards solidifying the project's place in meme history, with community members encouraging others to 'get Lennyfied'.

Marathon Petroleum Corp. engages in the refining, marketing, and transportation of petroleum products. It operates through the Refining and Marketing, and Midstream segments. The Refining and Marketing segment includes refining crude oil and other feedstocks, purchasing ethanol, and refined products for resale and distribution of refined products. The Midstream segment refers to transportation, storing, distribution, and marketing of crude oil and refined products. The company was founded in 1887 and is headquartered in Findlay, OH.

Marathon Petroleum Corp

Marathon Petroleum is trending amid unusual options activity and high trading volume, suggesting bullish sentiment among some investors. Community members are actively discussing potential ROI from call options, while recent reports highlight the company's solid financial position and potential as a 'refiner cash cow' given disruptions in global oil markets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cabaletta Bio (CABA) Upgraded to Buy: Here's Why

Cabaletta Bio (CABA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Cabaletta Bio shares hit their highest levels in nearly two months on Thursday following an announcement of crucial regulatory and clinical progress for its leading autoimmune therapy, rese-cel.CABA shares closed up 2.36% at $164.70 on Thursday.The company said it has expanded its RESET-Myositis trial with two new subtypes-specific patient cohorts containing approximately 15 patients each.&nbsp;The expansion followed the U.S. FDA's approval of RMAT designation for rese-cel, which shows its potential treatment for myositis in Americans who have few therapeutic options.The company plans to submit a Biologics License Application (BLA) for rese-cel in 2027 based on a registrational study design that follows FDA guidelines.&nbsp;The RESET clinical development program enrolled 44 patients and administered doses to 23 by May 9.The RESET trials for myositis, systemic autoimmune diseases, SLE/LN, and systemic sclerosis will reveal new clinical data during the EULAR 2025 Congress in June.&nbsp;Cabaletta intends to begin registrational discussions with the FDA regarding SLE and lupus nephritis during Q3 2025, followed by conversations about systemic sclerosis in Q4 2025.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 3,500% surge in 24-hour message volume.Some traders said they reached one of their target prices for CABA and have exited their positions but remain optimistic about a possible upward move tomorrow, keeping an eye out for re-entry opportunities.&nbsp;<stembedurl>https://stocktwits.com/Mr_Stochastic/message/614829609</stembedurl>Another user highlighted that after-hours trading already accounted for a third of the daily volume within the first hour, expressing bullish expectations for the stock to open higher and potentially reach $10 within six months.<stembedurl>https://stocktwits.com/alecsalaur198/message/614824832</stembedurl>The stock has declined 55% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cabaletta Bio Stock Surges To 2-Month High On Autoimmune Therapy Progress; Retail’s Pleased

The company announced the addition of two subtype-specific cohorts to its RESET-Myositis trial and received RMAT designation from the FDA for rese-cel.

Equity

Buy Rating Affirmed for Cabaletta Bio Amid Superior CD19 CAR T Therapy Efficacy in Autoimmune Disease Treatment

Wells Fargo analyst Derek Archila maintained a Buy rating on Cabaletta Bio (CABA Research Report) yesterday and set a price target of $20.00. Der...

Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake

Bloomberg / Contributor / Getty Images

 Key TakeawaysBillionaire Stanley Druckenmiller added more than three dozen new positions to his portfolio in the first quarter, including Apple, Reddit...

Citigroup Boosts Cabaletta Bio (NASDAQ:CABA) Price Target to $30.00

Cabaletta Bio (NASDAQ:CABA - Free Report) had its price objective lifted by Citigroup from $26.00 to $30.00 in a report published on Thursday morning, Benzinga reports. Citigroup currently has a buy...

Cabaletta Bio (NASDAQ:CABA) PT Raised to $30.00

Cabaletta Bio (NASDAQ:CABA - Get Free Report) had its target price raised by stock analysts at Citigroup from $26.00 to $30.00 in a research note issued to investors on Thursday, Benzinga reports...

Cabaletta Bio price target raised by $4 at Citi, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Cabaletta Bio (CABA, $16.83) Aroon Indicator entered a Downtrend on April 01, 2024.

For the last three days, A.I.dvisor has detected that CABA's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Cabaletta Bio (CABA, $17.04) Aroon Indicator entered a Downtrend on March 28, 2024.

Cabaletta Bio (CABA, $17.14) Aroon Indicator entered a Downtrend on March 27, 2024.

Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.

Cabaletta Bio Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Current Price	$2.36
Prev Close	$2.31
Open	$2.29
Dividend Yield	0.00%
50-Day Moving Average	$1.71
Beta	1.34
Avg. Volume	1.33M
PE Ratio	-0.87

52-Week High	$5.46
52-Week Low	$0.9857
Market Capitalization	$215.86M
EPS (Annual)	-$2.34
Price to Book	1.21
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

CABA
Cabaletta Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CABA News

CABA Cabaletta Bio Inc